CSX Corp. (CSX - Free Report) is one of the big American railroads. It reported strong earnings for the first quarter which beat the Zacks Consensus Estimate by 11 cents. Analysts are bullish and raising estimates for the full year. Earnings are expected to grow in the double digits this year and next. CSX is trading more like a technology stock than an old railroad. Shares are up 26% year-to-date and have a 20-year return of over 1500%. CSX is a Zacks Rank #2 (Buy).
BioTelemetry (BEAT - Free Report) is a healthcare innovator in the remote medical technology category, especially in the heart area. It has teamed up with Apple in collecting heart data. Shares are down 7% year-to-date and now trade with a forward P/E of just 28. The company reports earnings on Apr 25. It’s a Zacks Rank #1 (Strong Buy).
Should these three companies be on your investing short list? Find out in this week’s video.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
CSX Corp. (CSX - Free Report) is one of the big American railroads. It reported strong earnings for the first quarter which beat the Zacks Consensus Estimate by 11 cents. Analysts are bullish and raising estimates for the full year. Earnings are expected to grow in the double digits this year and next. CSX is trading more like a technology stock than an old railroad. Shares are up 26% year-to-date and have a 20-year return of over 1500%. CSX is a Zacks Rank #2 (Buy).
BioTelemetry (BEAT - Free Report) is a healthcare innovator in the remote medical technology category, especially in the heart area. It has teamed up with Apple in collecting heart data. Shares are down 7% year-to-date and now trade with a forward P/E of just 28. The company reports earnings on Apr 25. It’s a Zacks Rank #1 (Strong Buy).
Should these three companies be on your investing short list? Find out in this week’s video.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on CSX - FREE
Get the latest research report on BEAT - FREE